Buy Tirzepatide - HPLC-Verified Dual GLP-1/GIP | Regena

Tirzepatide is a 39-amino-acid synthetic peptide engineered to engage both the GLP-1 and GIP receptors with balanced potency. A C20 fatty diacid moiety at the Lys20 side chain enables high-affinity, reversible albumin binding, which is the design feature responsible for the long circulating half-life that has made tirzepatide the gold-standard dual incretin in preclinical research.

The molecule was designed on a GIP backbone rather than a GLP-1 backbone, and structural work indicates it engages the GLP-1 receptor with a distinct binding geometry compared with native GLP-1 or semaglutide. That biased-agonism profile is one of the reasons tirzepatide behaves differently on β-cell cAMP kinetics, receptor internalisation and downstream signalling than a pure GLP-1 mono-agonist at equimolar exposure.

Laboratory teams typically use tirzepatide as a benchmark against semaglutide (GLP-1 mono-agonist) and retatrutide (triple GLP-1/GIP/glucagon agonist) to study receptor crosstalk, β-cell signalling, lipid handling, adipose-tissue remodelling and hypothalamic appetite circuitry. The long pharmacokinetic profile supports chronic-exposure rodent models without daily dosing, which is a practical advantage when protocols run across weeks or months.

Regena releases tirzepatide against a defined analytical specification, not against marketing copy. Minimum release criteria are ≥99.0% HPLC main-peak purity by reverse-phase HPLC, mass-spectrometry identity confirmation against the calculated monoisotopic mass, peptide content by nitrogen analysis within the compound-specific window, water content by Karl Fischer under specification for a lyophilised product, and appearance and solubility checks against the internal release specification.

Related-impurity profiling flags any single unknown impurity above the reporting threshold, which is the correct place to catch process artefacts, deamidation products and long-storage degradants before a batch is released into the field. Batches that fail any element of the specification are held rather than shipped — an institutional and clinic audience is exactly the wrong place to discover an out-of-spec batch downstream.

Every Regena tirzepatide batch is tested by an independent European peptide laboratory — Janoshik Analytical by default — before any vial is released. The per-batch COA reports HPLC main-peak purity, peptide content by nitrogen, mass-spectrometry identity confirmation and a moisture figure by Karl Fischer, alongside the release date and the analytical laboratory identifier.

Buyers can download the per-batch report from the Regena lab reports page, cross-referenced by the batch number printed on the vial cap. There is no aggregated, marketing-only COA — every report ties to a real, traceable production lot, and orthogonal verification from a second laboratory (peptide mapping, residual-solvent GC-MS, endotoxin) can be pre-arranged for institutional buyers before dispatch.

Lyophilised tirzepatide ships under inert atmosphere as a sterile white powder in 2 mg, 5 mg, 10 mg and 15 mg fills. Hold the unopened vial at 2–8 °C on arrival; for kits that will not be reconstituted within 8–12 weeks, transfer to −20 °C for long-term storage. Reconstitute with bacteriostatic water containing 0.9% benzyl alcohol — this gives reliable in-use stability for 28 days under refrigeration for the reconstituted stock.

Most research protocols favour a 5 mg/ml or 10 mg/ml stock concentration for accurate microlitre dispensing. Direct the bacteriostatic-water stream against the glass wall of the vial rather than onto the lyophilised cake, then invert or swirl until the solution is clear. Do not vortex aggressively and do not shake — mechanical stress is a documented cause of aggregation in albumin-binding incretin analogues.

Aliquot before any freeze. Repeat freeze-thaw is the single largest source of measurable potency loss in long-acting incretin analogues (semaglutide, tirzepatide, retatrutide), and visual appearance is a poor indicator of integrity once cycling has occurred. Keep reconstituted vials away from direct light and record the reconstitution date on the label so the 28-day in-use window is unambiguous.

Regena dispatches tirzepatide from the Andalucía hub with same- or next-day delivery across Marbella, Málaga, Fuengirola, Estepona and the wider Costa del Sol. National Spanish coverage is typically 24–48 hours via tracked courier, and cross-border EU shipping to Germany, France, Italy, Portugal, the Netherlands, Belgium, Austria, Poland and Scandinavia is handled by DHL Express with end-to-end tracking and pre-cleared research-use customs paperwork.

Every EU shipment carries the matching batch COA and a research-use customs declaration so the parcel clears border handling without delay. Vials travel in temperature-buffered mailers sized for the transit window so lyophilised material arrives within specification; refrigerate at 2–8 °C on arrival. The consultations team can confirm import status for any specific EU country and format MSDS, CoO and CoC bundles for institutional procurement before an order is placed.

UK research clients order tirzepatide through the same Regena catalogue. Tracked dispatch from the European hub typically lands in 2–4 working days; DHL Express options are available for laboratories that need faster handover. Brexit-era VAT and customs handling are quoted transparently at checkout — no surprise import charges on delivery, and no undisclosed handling fees at the courier's UK entry point.

All UK orders ship with the same independent Janoshik COA used for EU clients. Additional paperwork (MSDS, certificate of origin, certificate of conformance) is supplied on request before dispatch, formatted for UK university, research-institute and hospital-affiliated procurement workflows.

US-based research clients receive tirzepatide via discreet, fully tracked international dispatch. Vials ship in temperature-buffered packaging sized to maintain cold-chain integrity across the longer transit windows typical of transatlantic delivery, and the accompanying COA is identical to the document supplied to European laboratories — same analytical laboratory, same specification, same release criteria.

US buyers should confirm institutional research-purchasing policy before ordering. Material is supplied strictly for research use and is not approved for human consumption in any jurisdiction. The consultations team can pre-clear documentation and coordinate express handling for time-sensitive US laboratory schedules.

Semaglutide engages GLP-1 alone; tirzepatide adds GIP receptor activity with balanced potency; retatrutide adds a third arm via glucagon receptor agonism. In preclinical models tirzepatide typically outperforms semaglutide on lipid metabolism, hepatic-steatosis and insulin-sensitivity endpoints at matched exposure, while retatrutide tends to push energy-expenditure and fat-mass measurements higher again through its glucagon component.

Laboratories building comparative panels often stock all three from Regena to keep batch documentation, dispatch logistics and packaging consistent across the panel. Where a study requires matched release dates across compounds, the consultations team will reserve co-dispatched lots so a comparator panel starts and ends on the same analytical footing. See the /research/retatrutide-vs-tirzepatide-comparison and /compare/tirzepatide-vs-semaglutide pages for deeper side-by-sides.

Regena tirzepatide is supplied strictly for in-vitro and preclinical research use. It is not a medicine, is not approved for human consumption in Spain, the wider European Union, the United Kingdom, the United States or any other jurisdiction Regena ships into, and is not dispensed against a prescription. The research-use declaration is included with every shipment alongside the COA.

Institutional buyers should ensure their tirzepatide work complies with the relevant institutional ethics framework and any local research-material handling rules. The Regena consultations team can pre-clear documentation questions — including MSDS, CoO, CoC and ISO certificate references — before any vial is dispatched.

Any honest tirzepatide supplier publishes the per-batch third-party COA, names the testing laboratory, prints the batch number on the vial and can tell you the release date without checking. Reject suppliers that recycle a single static COA across every batch, refuse to identify their analytical partner, decline to release related-impurity data, or quote prices below the realistic cost of independent HPLC and MS testing — those are leading indicators of unverified or relabelled product.

Regena's consultations team walks new buyers through the COA, reconstitution maths, stock-concentration options and storage plan before any order is dispatched. Quality is the product, and every downstream experimental result depends on the batch that started the workflow.